| | April 18th 2020 | Read in browser | | | |
| | | | | | The Economist this week | | | | | | Our coverage of the new coronavirus | | | | | | | | | |
| | | | | | | | | | Welcome to the newsletter highlighting The Economist’s best coverage of covid-19. Our cover leader this week asks whether China will be the pandemic’s big geopolitical winner. After a disastrous cover-up, China has brought the number of newly reported cases to a virtual halt. Factories there are reopening and researchers testing potential vaccines. By comparison Britain, France, Spain, Italy and America look as if they are struggling. Some warn that the disease will be remembered not only as a human catastrophe, but also as a geopolitical turning-point away from the West. Are they right?
Our covid-19 coverage in this week’s issue reports on the race for a vaccine—and the challenge of making it in sufficient quantities. We examine plans to relax lockdowns and look at how apps might make the job easier. We describe how South Africa is drawing on its bitter experience with HIV/AIDS. Our science team asks you not to blame the bats and our Middle East specialists report on the anti-covid-19 quack remedies doing the rounds in Iran: please don’t try them at home.
We have also been focusing on the disease in Economist Radio and in Economist Films. In our science podcast, Babbage, this week we delve further into the global search for a vaccine. We speak to Dr Seth Berkley, the chief executive of GAVI, the Vaccine Alliance. And Dr Trevor Drew of the Australian Centre for Disease Preparedness tells about two trials that have reached the animal-testing stage.
I hope you enjoy this taste of our coverage of the new coronavirus. For more reporting of how it is touching almost every part of our lives--from Brazilian soap operas to corporate fraudsters--please visit our website. | | | | | | Zanny Minton Beddoes, Editor-in-Chief | | | | | | | | |
| | This e-mail has been sent to: newsletter@gmail.com If you'd like to update your details please click here (you may need to log in). Replies to this e-mail will not reach us.
If you no longer wish to receive this newsletter, unsubscribe here.
| | | | | | |